Genecast RNA Fusion Focus is our proprietary targeted RNA sequencing, NGS-based test for multi-gene mutation detection of multiple types of solid tumors, including breast cancer, colorectal cancer, gastric cancer, lung cancer and prostate cancer.
Genecast RNA Fusion Focus detects fusion genes and associated SNVs, and gene transcription expression in 35 genes in RNA extracted from FFPE tissue samples.
Genecast RNA Fusion Focus detects 13% more fusion genes with high repeatability compared to other NGS-based DNA gene mutation detection methods.
It combines genetic testing by sequencing the complementary DNA (“cDNA”) from RNA of FFPE tissue samples with analysis against a proprietary database and algorithm, to determine gene variants and provides a targeted therapy recommendation.
The detection of gene variants in the FFPE tissue samples provided by patients with solid tumors is followed by selection of the most effective targeted therapy for the patient.
Genecast RNA Fusion Focus can be tested in combination with Genecast Comprehensive.
Our Genecast RNA Fusion Focus has the following advantages:
Comprehensive: Genecast RNA Fusion Focus provides comprehensive detection of gene fusions and rearrangements associated with targeted therapies. It also provides detection of all fusion forms.
Precise: Genecast RNA Fusion Focus is based on NGS-based targeted RNA sequencing recommended by NCCN guidelines for detection of gene fusions for NSCLC and colorectal cancer. It provides precise fusion detection and improved fusion detection rate of over 13% compared to other NGS-based DNA gene mutation detection methods. Genecast RNA Fusion Focus provides more opportunities for treatment with its ability to discover rare and unknown fusions that cannot be detected by traditional detection methods. In addition, it is able to detect fusions directly at the transcriptome level at a high detection rate, providing detection results that are relevant to clinical practice.